Announcements
- Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
- Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
- Presentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio’s Next Generation COVID-19 Vaccine
- Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million
Key statistics
On Friday, Gritstone bio Inc (2JQ:BER) closed at 0.7165, 10.40% above the 52 week low of 0.649 set on Apr 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.6895 |
---|---|
High | 0.7165 |
Low | 0.6895 |
Bid | 0.6865 |
Offer | 0.715 |
Previous close | 0.699 |
Average volume | 768.00 |
---|---|
Shares outstanding | 108.57m |
Free float | 105.98m |
P/E (TTM) | -- |
Market cap | 84.00m USD |
EPS (TTM) | -1.57 USD |
Data delayed at least 15 minutes, as of May 31 2024 19:08 BST.
More ▼